To evaluate the risk of exposure and seroconversion to SARS-CoV-2, we analysed IgA in preference to IgG or IgM, as levels of the latter are not only significantly lower in asymptomatic SARS-CoV-2-positive individuals than in COVID-19 patients [9], whilst IgA levels are higher and seroconversion occurs within 2 days of infection compared with up to 32 days for IgG and IgM [91]. Here, CD79A is linked to COVID-19.